Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash & Equivalents (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Cash & Equivalents for 4 consecutive years, with $132.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 55.31% to $132.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $132.8 million, a 55.31% decrease, with the full-year FY2025 number at $132.8 million, down 55.31% from a year prior.
  • Cash & Equivalents was $132.8 million for Q4 2025 at Phathom Pharmaceuticals, down from $138.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $384.3 million in Q4 2023 to a low of $130.1 million in Q1 2023.
  • A 4-year average of $222.0 million and a median of $210.1 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 149.92% in 2024, then plummeted 59.11% in 2025.
  • Phathom Pharmaceuticals' Cash & Equivalents stood at $155.9 million in 2022, then skyrocketed by 146.49% to $384.3 million in 2023, then dropped by 22.64% to $297.3 million in 2024, then crashed by 55.31% to $132.8 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Cash & Equivalents are $132.8 million (Q4 2025), $138.0 million (Q3 2025), and $149.6 million (Q2 2025).